TCS Catheter Lock Solution
….an Anti-Microbial Lock Solution providing patency and infection control
….a revolutionary approach to catheter maintenance
The Researchers New Best Friend
Components :
TCS combines two active ingredients vital to the effective management of vascular access catheters – Taurolidine and Citrate. When catheters are locked with TCS, their internal flow passages are resistant to clot formation & hostile to bacterial and fungal growth.
Taurolidine
- – chemically modified amino acid taurine
- – inhibits biofilm that can allow protected microbial colonization
- – prevents intraluminal microbial colonization
- – interacts with components of microbial cell resulting in irreparable injury
- – acts effectively against a broad range of bacteria and fungi
- – does not induce development of resisitant microbes
Citrate
- – anticoagulant component of TCS
- – forms a complex with calcium in the blood, disrupting the normal coagulation cascade
- – inhibits intraluminal blood coagulation with no systemic effect
Advantages :
Prevention of catheter related infection
Taurolidine has broad spectrum antimirobial activity against gram-positive and gram-negative bacteria,yeast and fungi
Reduced risk of biofilm formation
Taurolidine causes a loss of microbial fimbriae and flagellae, altering the microbial surface, preventing colonization
Supports catheter patency
The citrate ion chelates calcium ions in the blood by forming calcium citrate an complexes, disrupting the clotting mechanism.
No development of resistance
Taurolidine has broad spectrum antimirobial activity against gram-positive and gram-negative bacteria, yeast and fungi
Favorable safety profile
No systemic nor toxic effects of Taurolidine have been identified. Its’ safety has been an confirmed in clinical studies with long term intravenous
Bibliography :
Betjes M. et. al. “Preventions of dialysis catheter-related and sepsis with a citrate -taurolidine-containing lock solution”. 2004
Koldenhoff M. et. al. “Taurolidine is effective in an the treatment of central venous catheter-related bloodstream infections in cancer patients”. 2004
Jurewitsch B .et. al. “Taurolidine Lock: the key to prevention of recurrent catheter-related bloodstream infections”. 2005
Mandolfo S. et. al. “Catheter lock solutions:it’s time for a change.” 2006
Bradshaw JH. et. al. “Taurolidine and catheter related bloodstream Infection: A systematic review of the literature”. 2008
Simon A. et. al. “Taurolidine-citrate lock solution significantly reduces CVAD-associated gram-positive infections in pediatric cancer patients”. 2008
